HistoSonics scores reimbursement win for sonic beam therapy

The Edison histotripsy system. [Image courtesy of HistoSonics]HistoSonics announced today that the Centers of Medicare & Medicaid Services (CMS) set a new payment rate for its tumor treatment.

Minneapolis-based HistoSonics develops a histotripsy treatment for liver tumor procedures. Last month, the FDA granted de novo authorization for its Edison system and novel histotripsy therapy platforms.

Edison, an image-guided sonic beam therapy system uses advanced imaging and proprietary sensing technology. It delivers non-invasive, personalized treatments with precision and control. The system received FDA investigational device exemption in February. In March, HistoSonics announced the first kidney tumor treatment with its novel therapy system.

CMS set a new payment rate for this therapy, increasing the payment to $17,500. In its rule-making process, CMS utilized claims data from the HistoSonics #HOPE4LIVER trial in the U.S. to increase the outpatient payment…

Read more
  • 0

FDA grants de novo nod to HistoSonics histotripsy system

The Edison histotripsy system. [Image courtesy of HistoSonics]HistoSonics announced today that the FDA granted de novo authorization for its Edison system and novel histotripsy therapy platforms.

Edison, an image-guided sonic beam therapy system uses advanced imaging and proprietary sensing technology. It delivers non-invasive, personalized treatments with precision and control. The system received FDA investigational device exemption in February. In March, HistoSonics announced the first kidney tumor treatment with its novel therapy system.

The company believes Edison’s mechanism of action could provide significant advantages to patients. Those include the ability of the treatment site to recover and resorb quickly. Additionally, the platform enables physicians to monitor the destruction of tissue under continuous, real-time visualization and control.

Minneapolis-based HistoSonics says the de novo nod makes Edison the first and only histotripsy platf…

Read more
  • 0

Medical Alley startups achieve ‘relatively normal’ funding despite pandemic

Medical Alley Association member startups pulled in more than $256 million in funding through June, signaling a “relatively normal” first half of the year 2020 despite the COVID-19 pandemic and battered economy, according to the Minnesota-based trade group.

In total, 40 companies raised $256,406,357 in the first 6 months of the year. The $1.75 million median raise falls behind last year’s record $1.99 million as the second highest median raise for a first half in the last 5 years, indicative of a class of companies that took earlier-stage rounds in previous years and have successfully grown and matured.

Get the full story on our sister site, Medical Design & Outsourcing.

Read more
  • 0